Myomo, Inc. (MYO)
| Market Cap | 47.53M +30.2% |
| Revenue (ttm) | 43.26M +6.1% |
| Net Income | -14.51M |
| EPS | -0.37 |
| Shares Out | 39.61M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 301,257 |
| Open | 1.240 |
| Previous Close | 1.240 |
| Day's Range | 1.195 - 1.305 |
| 52-Week Range | 0.605 - 1.885 |
| Beta | 1.58 |
| Analysts | Strong Buy |
| Price Target | 4.64 (+286.67%) |
| Earnings Date | Nov 9, 2026 |
About MYO
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient’s weak or paralyzed arm to enable and improve functional activities of daily living. It also provides MyoPro 2 that includes control technology, configuration software and user interface, and pop-out battery for extended use of the bra... [Read more]
Financial Performance
In 2025, Myomo's revenue was $40.93 million, an increase of 25.73% compared to the previous year's $32.55 million. Losses were -$15.57 million, 151.9% more than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for MYO stock is "Strong Buy." The 12-month stock price target is $4.64, which is an increase of 286.67% from the latest price.
News
Myomo names Mary-Katherine McClure as Chief Commercial Officer
Myomo (MYO) “announced the appointment of Mary-Katherine McClure as Chief Commercial Officer effective October 12, 2026, succeeding Micah Mitchell, who will be departing following a leadership transit...
Myomo Appoints Mary-Katherine McClure as Chief Commercial Officer
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurol...
Myomo Transcript: H.C. Wainwright 28th Annual Global Investment Conference
The company is accelerating growth through expanded referral networks, O&P channel partnerships, and new product launches, supported by improved margins and reduced cash burn. Key innovations include a hand-only device for Germany and the AI-enabled MyoPro 3.0, with clinical trials underway to support broader reimbursement.
Myomo management to meet virtually with Craig-Hallum
Virtual Meeting to be held on September 21 hosted by Craig-Hallum.
Myomo to Present at the H.C. Wainwright 28th Annual Global Investment Conference
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurol...
Myomo price target raised to $10.50 from $10 at Ascendiant
Ascendiant raised the firm’s price target on Myomo (MYO) to $10.50 from $10 and keeps a Buy rating on the shares. The company reported Q2 upside and raised its 2026…
Myomo sees Q3 revenue $11.5M-$12M, consensus $11.16M
“In the third quarter of 2026, we expect continued year-over-year revenue growth with modestly higher operating expenses on a sequential basis, as we expand our MyoConnect program. We expect third…
Myomo sees FY26 revenue $45M-$47M, consensus $44.43M
“We are raising our full year revenue guidance to $45 million to $47 million. We reiterate our full year operating leverage expectation, and we expect cash burn to be less…
Myomo reports Q2 EPS (9c), consensus (10c)
Reports Q2 revenue $11.7M, consensus $10.35M. “I am pleased to report that the evolution of our go-to-market approach is driving positive results. Revenue of $11.7 million exceeded our expectations, w...
Myomo Earnings Call Transcript: Q2 2026
Q2 2026 revenue grew 21% year-over-year to $11.7M, with recurring patient sources now 53% of revenue and gross margin up to 72.1%. Full-year guidance was raised to $45–$47M, and operating loss and cash burn improved significantly.
Myomo Earnings release: Q2 2026
Myomo released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Myomo Quarterly report: Q2 2026
Myomo has published its Q2 2026 quarterly earnings report on August 5, 2026.
Myomo Reports Second Quarter 2026 Financial and Operating Results
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO)(“Myomo” or the “Company”), a wearable medical robotics platform company that offers increased functionality for those suffering fro...
Myomo to Report Second Quarter 2026 Financial Results on August 5
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurol...
Myomo Transcript: IAccess Alpha Virtual Best Ideas Summer Investment Conference 2026
The presentation highlighted strong growth in recurring patient sources, expanded insurance coverage, and a multi-billion dollar market opportunity for a proprietary wearable device addressing upper limb paralysis. Financials show improving margins and operational leverage, with a clear path to $100 million in annual revenue.
Myomo Slides: Investor presentation
Myomo has posted slides in relation to its latest quarterly earnings report, which was published on June 23, 2026.
Myomo Announces Participation in iAccess Alpha Virtual Best Ideas Summer Investment Conference
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurol...
Myomo Transcript: Sidoti Micro-Cap Virtual Conference
The company leverages a first-mover advantage in wearable robotics for upper extremity paralysis, expanding market access and recurring revenue streams through payer contracts and referral programs. Product innovation, clinical validation, and operational efficiency drive growth, with a focus on reaching cash flow break-even as recurring revenues rise.
Myomo Transcript: A.G.P.'s Annual Virtual Healthcare Conference
A proprietary orthotic device for stroke survivors is driving growth through expanded Medicare coverage, recurring revenue channels, and partnerships with national providers. Revenue guidance for 2024 is $43–$46 million, with a reduced break-even point and targeted lower cash burn.
Myomo Slides: Investor presentation
Myomo has posted slides in relation to its latest quarterly earnings report, which was published on May 20, 2026.
Myomo Announces Participation in Upcoming Investor Conferences
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurol...
Myomo Proxy statement: Proxy filing
Myomo filed a proxy statement on May 14, 2026, providing details for shareholder voting and corporate governance matters.
Myomo Proxy statement: Proxy filing
Myomo filed a proxy statement on May 14, 2026, providing details for shareholder voting and corporate governance matters.
Myomo Slides: Corporate presentation
Myomo has posted slides in relation to its latest quarterly earnings report, which was published on May 14, 2026.
Myomo Appoints Joseph M. Manko to its Board of Directors
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurol...